首页> 外文OA文献 >International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature
【2h】

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

机译:国际基础和临床药理学联盟。 LXXVIII。溶血磷脂受体命名法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lysophospholipids are cell membrane-derived lipids that include both glycerophospholipids such as lysophosphatidic acid (LPA) and sphingoid lipids such as sphingosine 1-phosphate (S1P). These and related molecules can function in vertebrates as extracellular signals by binding and activating G protein-coupled receptors. There are currently five LPA receptors, along with a proposed sixth (LPA1-LPA6), and five S1P receptors (S1P1-S1P5). A remarkably diverse biology and pathophysiology has emerged since the last review, driven by cloned receptors and targeted gene deletion (“knockout”) studies in mice, which implicate receptor-mediated lysophospholipid signaling in most organ systems and multiple disease processes. The entry of various lysophospholipid receptor modulatory compounds into humans through clinical trials is ongoing and may lead to new medicines that are based on this signaling system. This review incorporates IUPHAR Nomenclature Committee guidelines in updating the nomenclature for lysophospholipid receptors (http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=36).
机译:溶血磷脂是细胞膜来源的脂质,包括甘油磷脂(例如溶血磷脂酸(LPA))和鞘磷脂(例如鞘氨醇1-磷酸酯(S1P))。这些和相关分子可以通过结合和激活G蛋白偶联受体在脊椎动物中发挥细胞外信号的作用。当前有五个LPA受体,以及拟议的第六个(LPA1-LPA6)和五个S1P受体(S1P1-S1P5)。自上次综述以来,在小鼠中克隆受体和靶向基因缺失(“敲除”)研究的推动下,出现了极为多样化的生物学和病理生理学,这暗示了大多数器官系统和多种疾病过程中受体介导的溶血磷脂信号传导。各种溶血磷脂受体调节化合物正在通过临床试验进入人体,目前仍在进行中,可能会导致基于该信号系统的新药的问世。这篇综述结合了IUPHAR命名委员会指南,以更新溶血磷脂受体的命名法(http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=36)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号